Bristol-Myers Squibb has been granted a patent for a method to determine treatment doses for systemic lupus erythematosus (SLE) by measuring IKZF3 gene expression levels in patient samples. A higher expression score indicates a recommended daily dose of 0.45 mg or more of the specified treatment compound. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of July 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Method for dosing treatment in systemic lupus erythematosus
The granted patent US12064437B2 outlines a method for determining the appropriate dosage of a treatment compound for patients diagnosed with systemic lupus erythematosus (SLE). The method involves measuring the gene expression level of IKZF3 in a biological sample from the subject. If the calculated score based on this gene expression exceeds a predetermined reference level, the recommended dosage of the treatment compound is set at 0.45 mg or higher per day. The patent specifies that the treatment compound can be a specific chemical formula, including various forms such as salts, hydrates, and stereoisomers. Additionally, the gene expression can be quantified through different methods, including protein, mRNA, or cDNA level assessments.
Further claims in the patent detail the administration of the determined dosage to the subject and provide specific scoring criteria for dosage adjustments. For instance, if the score is higher than -0.49, the dosage may be set at 0.45 mg or more per day. The scoring system can utilize the Log2 of the IKZF3 gene expression level relative to one or more reference genes, such as TFRC, ACTB, or GAPDH. The patent also allows for flexibility in dosage determination, suggesting potential dosages of 0.5 mg, 0.6 mg, or 0.7 mg per day based on the score. This method aims to personalize treatment for SLE patients, potentially improving therapeutic outcomes by tailoring dosages to individual gene expression profiles.
To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
